LUNGLIBERATION

The AeroPace Neurostimulation System restores independent breathing and enhances ventilator weaning

AeroPace Activates the Diaphragm to Enable Independent Breathing and Improve Ventilator Weaning

The AeroPace temporary transvenous diaphragm neurostimulation system stimulates the phrenic nerves that control the diaphragm using an intuitive catheter-based approach that fits seamlessly into existing critical care workflows.

Learn about AeroPace

The AeroPace System Outperformed Standard-of-Care in a Randomized Clinical Trial1

43%

Faster weaning from mechanical ventilation over 30 days

3.2

Fewer days on MV in the ICU

47%

Lower risk of reintubation or reconnection to ventilation

50%

Lower risk of tracheostomy

Explore the Evidence Reimbursement + NTAP

Lungpacer Press Release

Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation

AeroPace temporary transvenous diaphragm neurostimulation system now available to help critically ill patients breathe independently faster.

Read The Article

Lungpacer Press Release

Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy

STARI will investigate continual diaphragm neurostimulation to improve lung, diaphragm, cardiac and brain function at the earliest stages of mechanical ventilation

Read The Article

Lungpacer Press Release

Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule

Read The Article

Lungpacer Featured In

After Tragedy, an Entrepreneur’s Triumph

Brian Gormley of the Wall Street Journal publishes article on Lungpacer’s 15-year journey from a deeply personal mission

Read The Article
See All News

References
1. Dres, M. (2025) Am J Resp Crit Care Med:. doi: 10.1164/rccm.202505-1056OC – Per-protocol (>50% of required stimulations) data for the AeroPace group relative to the Control group.